File downloaded on 2026-11-27
Source URL: https://medicines.health.europa.eu/veterinary/en/600000049379

Cylanic 500 mg + 125 mg tablets for dogs

Authorised

- Amoxicillin trihydrate
- Potassium clavulanate

Product identification

Medicine name:
Cylanic 500 mg + 125 mg tablets for dogs

Active substance:
Amoxicillin trihydrate

Potassium clavulanate

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Amoxicillin trihydrate
574.03 milligram(s) / 1.00 Tablet

Potassium clavulanate

148.91 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QJ01CR02

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Germany

Available in:
Germany

Package description:
oPA/Alu/PVC - PVC/Alu heat sealed blister containing 10 tablets each.Package sizes:Cardboard box of 10 tablets.
oPA/Alu/PVC - PVC/Alu heat sealed blister containing 10 tablets each.Package sizes:Cardboard box of 30 tablets.
oPA/Alu/PVC - PVC/Alu heat sealed blister containing 10 tablets each.Package sizes:Cardboard box of 50 tablets.
oPA/Alu/PVC - PVC/Alu heat sealed blister containing 10 tablets each.Package sizes:Cardboard box of 100 tablets.
oPA/Alu/PVC - PVC/Alu heat sealed blister containing 10 tablets each.Package sizes:Cardboard box of 250 tablets.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Industrial Veterinaria S.A.

Marketing authorisation date:
10/05/2021

Manufacturing sites for batch release:
aniMedica GmbH
aniMedica Herstellungs GmbH
Industrial Veterinaria S.A.
Lelypharma B.V.

Responsible authority:
Federal Office Of Consumer Protection And Food Safety

Authorisation number:
402758.00.00

Date of authorisation status change:
10/05/2021

Reference member state:
Ireland

Procedure number:
IE/V/0582/003

Concerned member states:
Austria Belgium Bulgaria Croatia Cyprus Czechia Estonia Germany Greece Hungary Italy Latvia Lithuania Netherlands Poland Portugal Romania Slovakia Slovenia Spain

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)
Published on: 11/10/2026
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Combined File of all Documents

ie-puar-mr-iev0582003-cylanic-500--mg--125-mg-tablets-for-dogs-en.pdf